Ansell shares surge 6% on AGM and trading update

Ansell shares are up after management raised earnings guidance for the year.

| More on:
Health professional putting on gloves.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Earnings upgrade: FY26 adjusted EPS lifted to US$1.37 to US$1.49, up from US$1.33 to US$1.45, after stronger-than-expected first-quarter trading.
  • Tariffs managed: Ansell is offsetting higher US tariffs through price increases and reduced sourcing from China, thereby protecting profits.
  • Efficiency gains: The company’s productivity program has delivered $47 million in savings, with synergies from the KBU acquisition ahead of plan.

Shares in Ansell Ltd (ASX: ANN) surged on Tuesday after the personal protective equipment manufacturer delivered a better-than-expected trading update and raised its earnings outlook at its 2025 Annual General Meeting.

At the time of writing, the Ansell share price is up 6% to $36.48, with the market reacting strongly after the company raised its guidance.

Trading update

Management now expects FY26 adjusted earnings per share of US$1.37 to US$1.49, up from the previously provided range of US$1.33 to US$1.45.

The upgrade follows a solid start to the financial year for Ansell, with management reporting sales and margins tracking ahead of plan, buoyed by favourable foreign-exchange trends, lower freight costs, synergy gains from its Kimberly-Clark PPE business acquisition, and ongoing manufacturing productivity improvements

Whilst US tariffs have been a hot topic this year, Ansell has found ways to manage this shift by increasing its prices and reducing its sourcing from China, which faces higher US tariffs. Management's goal is to fully offset the impact of the tariffs through a range of measures designed to protect the bottom line.

Ansell also reported solid productivity gains as its Accelerated Productivity Investment Program (APIP) continues to deliver results. The program has generated $47 million in cost savings so far in FY25, and management is targeting $50 million in cost savings for FY26. The company is also investing in a new enterprise resource planning (ERP) system to streamline operations and unlock digital efficiencies.

The integration of Kimberly-Clark's PPE business (KBU) (Ansell's largest-ever acquisition) was completed ahead of schedule, achieving $5 million in cost synergies and prompting a lift in its FY27 synergy target from $10 million to $15 million.

Ansell also reaffirmed its $200 million on-market share buyback, with $29 million completed so far this year to date.

Foolish bottom line

After a few years of losing ground following the COVID pandemic hype, Ansell is a business that is finally finding its footing. Favourable exchange rates may have contributed to this positive trading update, but this is more than just luck.

The company is creating its own luck through disciplined price increases and operational efficiency gains. With tariff risks under control, synergies running ahead of plan, and earnings guidance upgraded, Ansell's 6% share price jump is earned.

Ansell shares are now up 30% from their tariffs-related lows from earlier this year, and investor confidence is growing once again. It looks like full steam ahead for Ansell.

Motley Fool contributor Kevin Gandiya has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ansell. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

Bell Potter names the best ASX healthcare shares to buy in 2026

Healthy returns could be on offer with these shares according to the broker.

Read more »

man cupping ear as if to listen closely, rumour, cochlear
Healthcare Shares

Why is everyone talking about Telix shares this week?

Let's see why this biotech stock has been on the move this week.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

This ASX stock is going parabolic, and I think it's still a buy

4DMedical shares are up nearly 500% in 2025, but improving revenue visibility suggests the growth story may not be over.

Read more »

ecommerce asx shares represented by santa doing online shopping on laptop
Healthcare Shares

Looking for ideas before Christmas? These 2 ASX shares stand out to me

Two ASX shares at opposite ends of the market are catching my attention as the year draws to a close.

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Opinions

Forget CSL shares, I'd buy this booming biotech stock instead

This ASX biotech stock has caught my eye this year.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?

The biopharmaceutical company's shares are tipped to soar next year.

Read more »

A male ASX investor sits cross-legged with a laptop computer in his lap with a slightly crazed, happy, excited look on his face while next to him a graphic of a rocket shoots upwards with graphics of stars scattered around it
Healthcare Shares

Up 10x since July, could this hot ASX stock be the next Droneshield?

Investors chase asymmetric upside and 4DMedical is one of the ASX's hottest stocks right now.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Is Medibank stock a buy for its 5.5% dividend yield?

This business is providing investors with very healthy dividends.

Read more »